The First Affiliated Hospital of Xiamen University

The incidence of lung cancer in pregnancy is increasing because of an increase in cigarette smoking among young women, air pollution, and advanced maternal age. This is the third case report of a woman with metastatic anaplastic lymphoma kinase (ALK)-pos. lung adenocarcinoma treated with alectinib during pregnancy. The patient was diagnosed with lung cancer at 26 wk′ gestation. Her condition rapidly progressed to disseminated intravascular coagulation accompanied by hypoxemia. After 5 days of treatment with alectinib 600 mg twice daily and best supportive care, the patient′s symptoms quickly resolved. She delivered a healthy male newborn at 39 wk′ gestation. At birth, the alectinib concentration was 4.3 times higher in maternal plasma than that in newborn plasma (299.0 vs 69.2 ng/mL). The concentrations of alectinib in the amniotic fluid and the placenta were 27.3 ng/mL and 1136.25 ng/g, resp. The alectinib concentration in the maternal milk (152 ng/mL) indicated that this drug could be excreted through the breast milk. At 12 mo after the diagnosis, the mother had recovered well, and no developmental anomalies were observed in the infant.

This research tested a nanoparticle biomaterial in improving diabetic retinopathy (DR). Poly(lactic co glycolic acid) (PLGA)-CeO2, composed of cerium oxide (CeO2) and PLGA, was chosen as the new nanocomposite for DR treatment. DR mouse models were constructed to test the anti-DR efficiency of polyethylenimine (PEI)-CeO2 and PLGA-CeO2. The infiltration efficiency test was conducted to study the transport performance of the delivery system, and the clin. effect of CeO2 was observed regarding the structural integrity, oxidative stress response, inflammatory reaction, and retinal ganglion cell (RGC) apoptosis in the retina tissue. We observed that the infiltration efficiency of PLGA-CeO2 was higher than that of PEI-CeO2, and PLGA-CeO2 could inhibit oxidative stress and inflammatory reaction. Furthermore, the clin. efficacy of PLGA-CeO2 in rescuing amotio retinae and reducing RGC apoptosis was superior to PEI-CeO2. Conclusively, PLGA-CeO2 has a significant capacity for antioxidation and reducing RGC apoptosis in mouse models, which can be a potential compound nanodrug for DR treatment in the future.

To investigate the association of the interaction between peroxisome proliferator-activated receptor gamma 2 (PPAR-γ2) gene polymorphism and glycosylated Hb (HbAlc) level with susceptibility to diabetic periodontitis (DP). A total of 259 DP patients and 257 patients with type 2 diabetes mellitus (T2DM) treated from August 2017 to Apr. 2020 were enrolled, and another 180 healthy subjects were selected as control group. The HbA1c level of T2DM patients was determined using automatic biochem. analyzer. PPAR-γ2 gene Pro12Ala polymorphism was detected by the dideoxy chain termination method. The risk factors for DP were analyzed by multivariate logistic regression model. The adjusted odds ratio (OR) and 95% confidence interval of PPAR-γ2 gene Pro12Ala polymorphism and HbA1c level for the risk of DP were estimated, and the interaction between Pro12Ala polymorphism and HbA1c level was analyzed. The risk of DP increased in T2DM patients with genotypes Pro12Ala (PA) and Pro12Ala (AA) (OR=2.529, OR=2.594, P<0.01). T2DM patients with 6%≤ HbA1c <8% or HbA1c ≥8.0% had significantly elevated risk of DP (OR=2.046, OR=3.105), and T2DM patients with HbA1c ≥8.0% had higher risk of DP than those with 6%≤ HbA1c <8% (P<0.01). There was a pos. interaction between HbA1c level and Pro12Ala (PA) and Pro12Ala (AA) (γ>1). Individuals with genotypes Pro12Ala (PA) or Pro- 12Ala (AA) are high risk population of DP. The interaction between these genotypes and HbA1c level facilitates the occurrence and development of DP. Measures should be taken to control HbA1c level or to regulate gene expression, so as to prevent DP.